Type “mitochondrial peptides” into YouTube and you’ll drown in thumbnails: SS-31 vs MOTS-c — which wins? Wrong question. They’re not rivals. They do completely different jobs, and the interesting research question isn’t which — it’s in what order.
The One-Line Answer
SS-31 fixes the hardware. MOTS-c upgrades the software.
SS-31 physically stabilises damaged mitochondrial membranes. MOTS-c is a signalling molecule that tells cells to build more mitochondrial capacity. A power station repair crew versus a memo from head office saying “build more power stations.”
SS-31: The Structural Repair Peptide
SS-31 (elamipretide) is a synthetic four-amino-acid peptide engineered in a lab. It concentrates 1,000–5,000× inside the inner mitochondrial membrane, where it binds cardiolipin — the phospholipid scaffolding that holds the membrane’s energy-producing folds together. In preclinical studies it stabilises membrane structure, restores electron transport chain flow, lifts ATP output and cuts reactive oxygen species at the source. In 2025 the pharmaceutical version became the first FDA-approved mitochondria-targeted peptide — full story in our elamipretide approval breakdown.
Deep dive: the complete SS-31 pharmacology profile.
MOTS-c: The Metabolic Messenger
MOTS-c is the opposite in almost every way. It’s natural — a 16-amino-acid peptide encoded inside mitochondrial DNA itself (in the 12S rRNA region). Your mitochondria literally write this memo themselves.
Rather than repairing structure, MOTS-c signals. In studies it activates AMPK (the cell’s master energy sensor), travels to the nucleus under metabolic stress, and switches on genes for glucose uptake, fat oxidation and mitochondrial biogenesis — building new capacity. Researchers call it an “exercise-mimetic” because it turns on many of the same pathways as training.
Side by Side
| SS-31 (Elamipretide) | MOTS-c | |
|---|---|---|
| Origin | Synthetic, lab-engineered | Natural, encoded in mitochondrial DNA |
| Size | 4 amino acids | 16 amino acids |
| Primary target | Cardiolipin, inner mitochondrial membrane | AMPK signalling, nuclear gene expression |
| Job | Stabilise + protect existing mitochondria | Signal for new capacity + metabolic adaptation |
| Analogy | Hardware repair | Software upgrade |
| Research focus | Ageing muscle, heart, kidney, oxidative stress | Metabolism, insulin sensitivity, exercise capacity |
| Human data | FDA-approved (Forzinity, Barth syndrome, 2025) | Preclinical + early human studies |
Why Order Matters: Repair First, Boost Second
Here’s the logic increasingly discussed in mitochondrial research — and the reason “which one wins” misses the point:
Asking damaged mitochondria to work harder is like flooring the accelerator in a car with a cracked engine block. MOTS-c’s signalling drives energy demand and biogenesis — but if the existing membranes are leaking electrons and spraying ROS, pushing throughput can simply produce more oxidative stress.
So the sequenced protocol runs:
- Prepare (SS-31): stabilise cardiolipin, restore membrane integrity, cut ROS — fix the engine
- Activate (MOTS-c): switch on AMPK, drive biogenesis and metabolic adaptation — now floor it
Different mechanisms, zero overlap, complementary timing. That’s why they’re studied as a stack rather than head-to-head.
If you’re weighing up the reactions people report on the activation half of that sequence, our guide to MOTS-C side effects and the cancer question explains why running MOTS-c on unrepaired mitochondria so often backfires.
The Research Stack, In Pens
Both are available as pre-filled Genesis research pens — no reconstitution, click-dial dosing:
- SS-31 Peptide Pen 20mg — £169, the repair phase
- MOTS-C KLIK PEN 40mg — £165, the boost phase
Both independently lab-tested to ≥99% purity — COA reports. For click conversions and research protocol structure, see the SS-31 dosing and cycles guide.
SS-31 vs MOTS-c: FAQs
Are SS-31 and MOTS-c the same type of peptide?
No. SS-31 is a synthetic membrane-stabilising tetrapeptide; MOTS-c is a natural mitochondrial-derived signalling peptide. They share a destination, not a mechanism.
Can SS-31 and MOTS-c be used together in research?
Yes — their mechanisms are complementary and they’re increasingly studied in combination, typically sequenced with SS-31 first.
Which has more human evidence?
SS-31, by a distance. Its pharmaceutical version (elamipretide/Forzinity) went through multiple clinical trial programmes and gained FDA approval in 2025. MOTS-c remains mostly preclinical.
Which is better for studying ageing mitochondria?
They answer different questions. SS-31 is the tool for membrane integrity, ATP efficiency and oxidative stress; MOTS-c is the tool for metabolic signalling and biogenesis. Many ageing studies need both.
Is NAD+ the same kind of thing?
No — NAD+ is a coenzyme, not a peptide. It’s a substrate the electron transport chain uses, rather than a repair or signalling agent.
The Takeaway
Stop asking which peptide wins. SS-31 restores the machinery; MOTS-c tells the machinery to do more. In research protocols they’re a sequence, not a competition — repair first, boost second.
Start with SS-31 Peptide Pen 20mg → | Then MOTS-C KLIK PEN 40mg →